Skip to content

IMMUNOMEDICS INC

Delisted

CIK 722830fmd_0N4V72Z5XRK0KEP10NF77BVWS9Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Jul 01, 2009 to Jun 30, 2020, 41 periods

Latest annual · FY2019

Millions
Total revenues
0
Gross profit
0
Operating income
(325)
Net income
(357)
Free cash flow
(229)

Latest quarter · Q2 FY2020

Millions
Total revenues
20
Gross profit
18
Operating income
(53)
Net income
(66)
Free cash flow
(32)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2016 to FY2019
-55.0%
Revenue, 5 yearsFY2014 to FY2019
-49.6%
Net income, 5 yearsFY2014 to FY2019
n/m

IMMUNOMEDICS INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2019FY2018ChangeSource
Revenue$295,000$2.2 million-86.3%10-K 2020-02-27 · proof
Gross profit$295,000$1.5 million-80.9%10-K 2020-02-27 · proof
Operating income-$324.8 million$141 million-330.3%10-K 2020-02-27 · proof
Net income-$357.2 million-$273.8 million10-K 2020-02-27 · proof
Cash from operating activities-$222.4 million-$134 million10-K 2020-02-27 · proof
Free cash flow-$229.3 million-$143.9 million10-K 2020-02-27 · proof
Total assets$671.7 million$528 million+27.2%10-K 2020-02-27 · proof
Total liabilities$404.5 million$262.2 million+54.3%10-K 2020-02-27 · proof
Cash and cash equivalents$608.6 million$492.9 million+23.5%10-K 2020-02-27 · proof
What was IMMUNOMEDICS INC's revenue in fiscal 2019?
IMMUNOMEDICS INC reported revenue of $295,000 for fiscal 2019 (the year ended Dec 31, 2019), against $2.2 million the year before (-86.3%). Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
What was IMMUNOMEDICS INC's gross profit in fiscal 2019?
IMMUNOMEDICS INC reported gross profit of $295,000 for fiscal 2019 (the year ended Dec 31, 2019), against $1.5 million the year before (-80.9%). Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
What was IMMUNOMEDICS INC's operating income in fiscal 2019?
IMMUNOMEDICS INC reported operating income of -$324.8 million for fiscal 2019 (the year ended Dec 31, 2019), against $141 million the year before (-330.3%). Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
What was IMMUNOMEDICS INC's net income in fiscal 2019?
IMMUNOMEDICS INC reported net income of -$357.2 million for fiscal 2019 (the year ended Dec 31, 2019), against -$273.8 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
What was IMMUNOMEDICS INC's cash from operating activities in fiscal 2019?
IMMUNOMEDICS INC reported cash from operating activities of -$222.4 million for fiscal 2019 (the year ended Dec 31, 2019), against -$134 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
What was IMMUNOMEDICS INC's free cash flow in fiscal 2019?
IMMUNOMEDICS INC reported free cash flow of -$229.3 million for fiscal 2019 (the year ended Dec 31, 2019), against -$143.9 million the year before. Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
What are IMMUNOMEDICS INC's total assets?
As of Dec 31, 2019, IMMUNOMEDICS INC reported total assets of $671.7 million, against $528 million a year earlier (+27.2%). Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
What are IMMUNOMEDICS INC's total liabilities?
As of Dec 31, 2019, IMMUNOMEDICS INC reported total liabilities of $404.5 million, against $262.2 million a year earlier (+54.3%). Source: the 10-K filed with the SEC on Feb 27, 2020. SEC
What are IMMUNOMEDICS INC's cash and cash equivalents?
As of Dec 31, 2019, IMMUNOMEDICS INC reported cash and cash equivalents of $608.6 million, against $492.9 million a year earlier (+23.5%). Source: the 10-K filed with the SEC on Feb 27, 2020. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:722830&period_type=annual&limit=5"

Information only, not investment advice.